Grants
Grants
Molecular characterization and behaviour of tumors arising in patients taking 5-alpha reductase inhibitors, Movember Discovery Grant Application, Approved June 2015
-
Robert J. Hamilton, MD MPH FRCSC, Staff Urologist, Princess Margaret Cancer Centre
Co-Investigator: Eshetu Atenafu, M.Sc., Pstat , Senior Biostatistician
Applying radiomics to predict pathology of residual retroperitoneal nodal masses in metastatic germ cell tumors following platinum based chemotherapy (Approved Aug 2015-Dec 2016)
PI: Jeremy Lewin, Philippe Bedard, Princess Margaret Cancer Centre
-
: Eshetu Atenafu, M.Sc., Pstat , Senior Biostatistician
PI Forsyth, Peter, Wang, L. et al: Phase I pharmacodynamic and “high content” study of the gamma-secretase inhibitor RO4929097 in patients with recurrent malignant gliomas (MGs) targeting p75NTR to inhibit brain tumour initiating cells (BTICs) and recurrent invasive gliomas CCSRI (2010-2012)
2019-2022 CIHR, Canadian Institutes of Health Research
Feasibility of integrating epigenomic and genomic liquid biopsy biomarkers into the clinical management of advanced prostate cancer
$544,119 – PI –S Sridhar;Co-I – W Xu
2019-2023 CIHR, Canadian Institutes of Health Research
Development of the first pre-operative serum exosomal miRNA test to guide treatment decision in prostate cancer
$750,000 – PI – W Xu, G Yousef, N Fleishman;Co-I – L Klotz
2019-2023 CIHR, Canadian Institutes of Health Research
Genomics-based radiosensitization for HPV-negative squamous cell carcinoma of the aerodigestive tract
$ 757,352 – PI – S Bratman;Co-I - W Xu
2018-2021 Prostate Cancer Canada
Combination of subpathology and noncoding RNA: integrating outcome prediction and treatment individualization for intermediate-risk prostate cancer
$1,499,250 – PI – Housheng He;Co-I - W Xu
2018-2022 CIHR, Canadian Institutes of Health Research
Early detection of cancer in high-risk patients through profiling of circulating tumour DNA
$1,977,525 – PI - T Pugh;Co-I - W Xu
2018-2021 Princess Margaret Cancer Centre Foundation
Artificial Intelligence, Data Science, and Microbiome Research
$1,000,000 – PI: W Xu, L Siu, B Haibe-Kains,B Coburn
2018-2020 CCC, Crohn’s and Colitis Canada
The Crohn’s and Colitis Canada GEM Project
$4,000,000 – PI: - K Croitoru;Co-I - W Xu
2017-2022 CIHR, Canadian Institutes of Health Research
Seeking Molecular Signatures for Nasopharyngeal Carcinoma
$1,147,500 – PI –F Liu; Co-I – W Xu
2017-2021 OICR, Ontario Institute for Cancer Research
Ovarian Cancer Translational Research Initiative
$10,000,000 – PI –A Oza, R Rottapel; Co-I – W Xu
2017-2022 NSERC, Natural Sciences and Engineering Research Council of Canada
Methodology Development and Implementation for Microbiome Sequencing Data: Hierarchical Modeling on Clustered Taxa Counts with Repeated Measures
$140,000 – PI –W Xu
2016-2018 CCSRI, Canadian Cancer Society Research Institute
Early detection of tumour response for adaptive therapy in oropharynx cancer
$200,000 – PI –S Bratman;Co-I – W Xu, F Liu, J Waldron, T Pugh
2016-2018 CIHR, Canadian Institutes of Health Research
X-chromosome wide genetic association on cancer prognostic and pharmacogenetic analysis of clinical trials: methodological development and analysis
$150,000 – PI –W Xu,G Liu; Co-I – R Hung, B Chen, C O’Callaghan
2016-2017 US DOD, Department of Defense
Identifying a reversible genetic factor that drives lung cancer in veteran African Americans to foster the early detection and prevention of lung cancer
$100,000 – PI –W Xu,D Reisman
2016-2017 Princess Margaret Cancer Foundation Invest in Research Grant
Impact of distinct HPV subtypes on survival in oropharyngeal cancer
$100,000 – PI – S Bratman; Co-I – W Xu, F Liu, J Bruce, T Pugh
2014-2016 McLaughlin Center Accelerator Grant
Early Detection of Lung Cancer Using Next Generation Sequencing Technology
$50,000 – PI –W Xu,G Liu; Co-I – R Hung, P Hu
2013-2014 OICR, Ontario Institute for Cancer Research
Pharmacokinetic and Pharmacogenetic analysis of NCIC CTG CO.20 and CO.17 Clinical Trials
$128,945 – PI –W Xu,G Liu; Co-I – E Morgen, LL Siu, X Chen, CJ O’Callaghan, A Brown, D Jonker, D Tu
2012-2015 CIHR, Canadian Institutes of Health Research
The Pharmacogenetics of Bevacizumab: A Companion Correlative Study of the Ovarian Cancer Clinical Trial, ICON7
$390,342 – PI – G Liu; Co-I – W Xu,R. Kim, H. MacKay, S
2012-2014 CCSRI, Canadian Cancer Society Research Institute
The relationship between local breast radiation with hematopoietic stem cell trafficking, and fatigue.
$198,320 – PI – FF Liu; Co-I – W Xu, M Li, M Minden,
Multivariate Association of Cardiovascular Disease Risk Factors in People with Type 1 diabetes, Fellowship Clinical Research Project. Funding Sources: 2016/9 - 2018/8, CIHR STAGE, Total Funding - 90,000 CAD
Travel Award 2017, Banting and Best Diabetes Center, 1000 CAD
Travel Award 2017, The Hospital for Sick Children, 1000 CAD
Travel Award 2016, Mc Laughlin Center, University of Toronto, 1000 CAD
CIHR STAGE (Strategic Training for Advanced Genetic Epidemiology) fellowship (2020-2022)
Grant Institutions
CIHR, Canadian Institutes of Health Research
Prostate Cancer Canada
Princess Margaret Cancer Centre Foundation
CCC, Crohn’s and Colitis Canada
OICR, Ontario Institute for Cancer Research
NSERC, Natural Sciences and Engineering Research Council of Canada
Children’s Oncology Group Adolescent and Young Adult AFLAC Grant
Banting and Best Diabetes Centre
The Hospital For Sick Children
Mc Laughlin Center, University of Toronto
